Therapeutics for gynecologic and obstetric conditions are most commonly provided via oral or intramuscular routes of administration. Oral administration is convenient but results in poor bioavailability and unwanted side effects. Intramuscular injections facilitate cellular absorption but pain and infections can reduce patient compliance. The proposed technology enables vaginal delivery of therapeutics for gynecologic and obstetric conditions. A glycol-chitin thermosensitive, mucoadhesive hydrogel adheres to the inner wall of the vagina and delivers therapeutics, such as progesterone, directly to the vagina. The drug can be released over time, increasing efficacy of drugs designed to target specific uterine tissues.

- Increased efficacy with site-specific drug delivery with low risk of leakage.
- Increased patient compliance through self-administration.
- Alleviates vaginal tissue irritation.

Recent Publications

INVENTOR PROFILE
Margut Janát-Amsbury, M.D., Ph.D., Assistant Professor - Gynecology and Obstetrics, School of Medicine
Matthew Peterson, M.D., Chair - Obstetrics and Gynecology, School of Medicine

DATE UPDATED: 1/23/2018